Clinical trial
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects…
NCT03301636 · NewLink Genetics Corporation, Industry · Terminated
Key facts
| NCT number | NCT03301636 |
|---|---|
| Title | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma |
| Official title | A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Adult Patients With Unresectable Stage III or Stage IV Malignant Melanoma |
| Acronym | NLG2107 |
| Lead sponsor | NewLink Genetics Corporation, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Pembrolizumab, Nivolumab, Indoximod |
| Enrollment | 21 |
| Start date | Dec 8, 2017 |
| Primary completion | Oct 21, 2019 |
| Completion | Nov 4, 2019 |
| First posted | Oct 4, 2017 |
| Last update posted | Sep 27, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: